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Abstract Congenital dyserythropoietic anemia type I
(CDA I) is a rare autosomal recessive disorder with
ineffective erythropoiesis, characteristic morphological
abnormalities of erythroblasts, and iron overloading.
CDA I is caused by mutations in the CDAN I gene,
encoding a protein named codanin-1. Complex bone
abnormalities, especially syndactyly, have not been
systematically described with this disease. We present
two cases of morphologically and genetically confirmed
CDA I with striking bone abnormalities and response to
treatment with alpha-interferon. Our cases clearly docu-
ment the association of skeletal anomalism with CDA I and
indicate that codanin-1 may play a role in the development
of the skeleton.
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Introduction
Congenital dyserythropoietic anemia type I (CDA I, MIM
224120) is a rare autosomal recessive disorder with
ineffective erythropoiesis, characteristic morphological
abnormalities of erythroblasts and peripheral red blood
cells and iron overloading independent of transfusions [1–
4]. CDA I is caused by mutations in the CDAN I gene
encoding codanin-1 [5, 6]. In the German CDA Registry,
103 cases out of 88 families could be identified from
published case reports and own unpublished observations.
Furthermore, 70 cases in a large Bedouin tribe were
described by Tamary et al. from Israel [7, 8]. Complex bone
abnormalities, especially acral dysostosis with syndactyly,
have occasionally been described with CDA I [9–14]. The
CDAN I gene was sequenced in only a few families with
dysostosis, and the relation of dysostosis with the defects in
erythropoiesis is not understood. In this paper, we present
two cases of morphologically and genetically confirmed
CDA I with striking bone abnormalities which share an
identical mutation in one but show a different mutation in
the other allele of the CDAN I gene. Both patients had a
significant response to treatment with alpha-interferon, as
shown before in almost all cases reported to receive this
type of therapy [4].
Case 1
The first patient (UPN 178/01 of the German CDA
Registry) is a 42-year-old Caucasian male from Switzerland.
Two siblings died immediately after birth and one sister as
well as both parents are healthy without anemia and with-
out bone malformations. The family was traced back for
four generations, all living within one area of Switzerland.
The proband presented with congenital anemia first docu-
mented at the age of 2 years and with acral dysostosis.
Skeletal dysmorphology consisted of mutual syndactyly of
the second and third toes with hypoplasia of the fourth
metatarsal and unilateral hypoplasia of the distal phalange
of the fourth left finger with an aplastic nail (Fig. 1). The
malformations of the feet prompted orthopedic corrections
shortly after adolescence, resulting in the missing fourth
metatarsals and scarred second and third toes (Fig. 1).
Besides these skeletal malformations, moderate bilateral
ptosis is present since childhood. Our patient grew up with
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chronic anemia disabling him from sportive activity.
Anemia occasionally required transfusion therapy in
childhood. Because of increasing organomegaly, splenec-
tomy was performed at the age of 9 years, without a
significant improvement of anemia. Mental development
was normal and the patient graduated as a chemist at the
age of 26 years. The diagnosis of CDA I was established
after correspondence with H.H. at the end of the 1970s by
C. Gasser who presented the two cases of this report at the
6th meeting of the International Society of Hematology in
Athens, 1981 [1]. After adolescence, the patient presented
stable anemia with hemoglobin concentrations of 8–9 g/dl
and a mean corpuscular volume (MCV) of 110–120 fl
without need for transfusions. He developed iron overload
that has been treated with subcutaneous deferoxamine with
fading compliance. Three years ago, the patient was
referred to our institution with significant iron overload.
According to the widely accepted diagnostic criteria [2],
the diagnosis of CDA I was confirmed and we started
chelation with deferoxamine and deferiprone. Further
analysis showed a compound heterozygous mutation of
the CDAN I gene with mutations in exon 24 [3259 insertion
(ins) T], leading to a frameshift (fs) at the protein level and
26 (C3503T, Pro1129Leu) [3]. Treatment with interfer-
on-α-2b (3×3 Mio IE per week) resulted in a significant
increase of hemoglobin. Tolerance of interferon was good
and quality of life improved extensively. As main side
effect, transitory asymptomatic neutropenia (minimal
500/μl) developed. After 6 months of therapy, we switched
to Peginterferon-α-2b. Tolerance was comparable to the
non-pegylated form of interferon. We again observed
asymptomatic neutropenia.
Case 2
The second patient (UPN 177/01 of the German CDA
Registry) is a 48-year-old Caucasian female from
Switzerland. One brother and both parents are not anemic
and show no skeletal malformations. The family was traced
back for two generations. Besides inborn anemia, the
proband has mutual malformations of her toes (Fig. 1) and
moderate bilateral ptosis like the first case. After birth and
during infancy, she received multiple transfusions. At the
age of 9 years, splenectomy and, 6 years later, syndactyly
correction of the third and fourth toes on the right foot
were performed. After splenectomy, the transfusion inter-
val was reduced, and after adolescence there was no need
for further transfusions. Because of increasing ferritin
levels, a liver biopsy was carried out at the age of 38, which
showed massive siderosis and beginning cirrhosis. An iron
chelating therapy was started with deferiprone and was
proved to be successful in a second biopsy 3 years later
with almost complete normalization of the former findings.
Fig. 1 Pictures of dysostosis in
CDA I. a X-ray photograph of
the feet of case 1. b Feet of case
1. c Hypoplasia of the distal
phalange of the fourth finger at
the left with nail hypoplasia of
case 1. d Right and left foot of
case 2
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Ferritin levels decreased to normal values and remained in
the normal range on continued therapy of very low dose of
deferiprone (500–1,000 mg/d). Hemoglobin levels were
stable during the last 10 years with concentrations of 9–
10 g/dl and a MCV of 100–120 fl. The patient suffered
from unspecific fatigue most probably related to moderate
anemia. A molecular analysis demonstrated a compound
heterozygous mutation of the CDAN I gene with affection
of exons 12 (A1910G, N598>S) and 24 [3259 ins T; fs] [3].
The parents of the mother, who shares the mutation on exon
24 with the proband, stem from the same region as the
parents of the mother of case 1, who also shows the
mutation on exon 24. The father originated from England.
We started a treatment with interferon-α-2b with the
intention to increase the hemoglobin concentrations and, in
the long term, to maintain normal ferritin levels without
chelation. Because of marked neutropenia after the initial
five doses (3×3 Mio units per week), we decreased the
dose of interferon to 2 Mio units per week. Since starting
the treatment, the hemoglobin levels are between 11 and
12 g/dl and the patient feels markedly more vital.
Discussion
The diagnosis of CDA I is based on the general diagnostic
criteria of the CDAs and characteristic abnormalities of
erythroblasts seen in light and electron microscopy [2, 3,
13, 15]. Most patients have a life-long moderate macro-
cytic anemia which is more severe in infancy and
childhood, requiring blood transfusions in this period but
not thereafter. Mutations of the CDAN I gene were more
recently detected in all members of the Bedouin tribes as
observed by scientists from Israel and in 22 out of 24
unrelated European families [3, 6, 16]. Although electron
microscopy was not done in the two patients described in
this report, they unequivocally fulfill the criteria of CDA I,
including mutations in the two alleles of the CDAN I gene.
The response to therapy with interferon-α is further support
of correct diagnosis.
Morphologic body abnormalities are observed in
approximately 10% of CDA I cases [13] and may be the
presenting features for the referral of children [12] to
specialized institutions. Among them, dysostosis is partic-
Fig. 2 Hemoglobin concentra-
tion and neutrophil count after
the beginning of interferon
treatment in case 1 (above)
and 2
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ularly frequent, consisting of foot and hand dysmorphol-
ogies as were seen in our patients (Fig. 1). The observation
that the two patients described show similar dysostosis of
both feet and that the patients share an identical exon 24
mutation of CDAN I allowed the hypothesis that either this
specific allele of CDAN I or a variation in a gene linked to
this allele at chromosome 15q15 may act dominantly and
be causative for the dysmorphologies. This hypothesis was
dismissed on the fact that the ancestors of both probands,
being heterozygotes for these mutations and coming from
the same region in Switzerland (and may therefore be
related, although this was not proven by pedigree data
available), were unaffected. In addition, as shown in
Table 1, similar patterns of dysostosis were observed in
unrelated families showing other CDAN I mutations,
excluding the specificity of the exon 24 mutation for
skeletal dysmorphologies.
In drosophila, the cytoplasmic codanin-1-like protein
discs lost (dlt) is needed for cell survival and cell cycle
progression. In the absence of dlt, the S phase of the cell
cycle cannot be completed and, thus, mitosis cannot be
initiated. A lack of dlt leads to a 30% reduction in the
number of blood cells in third instar larvae and to a variable
loss of imaginal discs [17]. These observations in dro-
sophila hint at the possibility that codanin-1 may be
involved in several developmental pathways, explaining
the human phenotype of dyserythropoietic anemia and
dysostosis in some cases.
The favorable response to interferon-α in the two
patients observed (Fig. 2) confirms similar data on patients
with CDA I, with the exception of three unrelated cases
from India [18]. There is not only an improvement of the
hemoglobin level but, in a long-term perspective, a
reduction of iron overload that can also be achieved [19].
As side effects of interferon can reduce the compliance and
may result in neutropenia, dose adjustments are required.
Our data, so far, confirm a decreased need for chelation
therapy among patients on an interferon regimen.
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